The Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine.

167.6K

views

31

authors

23

articles

The Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine.

167.6K

views

31

authors

23

articles

Editorial

03 February 2015

The Treatment of Metastatic Non-Small Cell Lung Cancer in a New Era of Personalized Medicine

Vera Hirsh

5,705 views

2 citations

Editors

2

McGill University

Barbara Melosky

University of British Columbia

Impact

Fetching...

About

Lung cancer is the leading cause of cancer related mortality in Canada and USA. Majority of the patients present in advanced stage of the disease and of these only about 2% will be alive at 5 years. NSCLC is the most common form of lung cancer,accounting for approximately 87% of cases.
Systemic chemotherapies have been used to treat metastatic NSCLC for decades,but the improvements of outcomes have reached a plateau.
Recent advances in understanding signalling pathways for malignant cells,their interconections,the importance of various receptors and biomarkers and the interplay between various oncogenes have led to the development of targeted treatments that are improving both efficacy and safety of the treatments.
Knowledge about the advantages of treatments with the targeted agents in metastatic NSCLC is growing rapidly. Combining various targeted agents or sequencing them properly will be important in the era of personalised medicine and overcoming development of the resistence to various targeted agents will be challenging.
The importance of a team work,from the diagnosis through various treatments,to supportive care,from the interventional radiologists, pneumologists or surgeons,who have to obtain a satisfactory tumor tissue specimen ,to pathologists,radiation and medical oncologists, to supportive care specialists,will be described in our publications. We will cover completely present and future approaches to personalised medicine in this rapidly evolving field of metastatic NSCLC.

Lung cancer is the leading cause of cancer related mortality in Canada and USA. Majority of the patients present in advanced stage of the disease and of these only about 2% will be alive at 5 years. NSCLC is the most common form of lung cancer,accounting for approximately 87% of cases.
Systemic chemotherapies have been used to treat metastatic NSCLC for decades,but the improvements of outcomes have reached a plateau.
Recent advances in understanding signalling pathways for malignant cells,their interconections,the importance of various receptors and biomarkers and the interplay between various oncogenes have led to the development of targeted treatments that are improving both efficacy and safety of the treatments.
Knowledge about the advantages of treatments with the targeted agents in metastatic NSCLC is growing rapidly. Combining various targeted agents or sequencing them properly will be important in the era of personalised medicine and overcoming development of the resistence to various targeted agents will be challenging.
The importance of a team work,from the diagnosis through various treatments,to supportive care,from the interventional radiologists, pneumologists or surgeons,who have to obtain a satisfactory tumor tissue specimen ,to pathologists,radiation and medical oncologists, to supportive care specialists,will be described in our publications. We will cover completely present and future approaches to personalised medicine in this rapidly evolving field of metastatic NSCLC.

Download ebook

Share

Editors

McGill University

Barbara Melosky

University of British Columbia

Impact

167,597 Total views

122,655 Article views

38,752 Article downloads

6,190 Topic views

Published In

Journal Thumbnail

Frontiers in Oncology

Thoracic Oncology

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic